This site uses technical and analytics cookies.
By continuing to browse, you agree to the use of cookies.

Menarini celebrates its 10th Anniversary in Singapore and continues investing in Asia Pacific

Menarini Asia Pacific celebrated its 10th Anniversary in Singapore on 11 November 2021. Privately owned and headquartered in Florence, Italy, the Group has a presence in 140 countries worldwide with a direct presence in 13 major markets across the region. Menarini is a leading biopharmaceutical company with a diverse portfolio of proprietary and partnered brands in a wide range of therapeutic areas. These include Consumer Health, Dermatology, Allergy/Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology/Specialty Care and Men’s Health.

Headquartered in Singapore, Menarini Asia-Pacific employs over 3,500 employees in the region with more than 80% having at least a graduate University Degree. Here in Singapore, Menarini is growing its staff strength to support the expansion plans. Menarini started with 80 employees in 2011, today it has 187 staff with plans to grow its numbers in the future. Currently, 63% are Singaporean and 17% are Singapore PRs who hail from across the globe.

At the same time, Menarini seeks to develop people outside its organisation in support of the government’s SG United initiative. Menarini has welcomed and trained individuals who have been retrenched in recent times due to the pandemic, with the aim of helping them keep their qualifications alive. Menarini currently has 6 trainees under its wing, who are deployed to various divisions within Menarini. These individuals have joined the company via the SG United Mid-Career and SG Traineeship Programmes.

Beyond various manufacturing and acquisitions in the Asia Pacific region, Menarini is strengthening R&D capabilities in Asia, beginning with Singapore. In October 2021, A. Menarini Biomarkers Singapore (MBS), signed a Memorandum of Understanding (MOU) with the SingHealth Duke-NUS Maternal and Child Health Research Institute (MCHRI). The aim is to develop an international medical hub for non-invasive diagnostics in prenatal and targeted therapies for better clinical outcomes.

MBS is also in the process of setting up a new laboratory in Singapore. This will become a cell-based, non-invasive prenatal diagnosis (CB-NIPD) hub for the entire region, paving the way for more such R&D collaborations in the region.